Jeffrey N. Simmons Sells 12,500 Shares of Eli Lilly and Company (LLY) Stock
Eli Lilly and Company (NYSE:LLY) SVP Jeffrey N. Simmons sold 12,500 shares of the stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $86.46, for a total value of $1,080,750.00. Following the completion of the transaction, the senior vice president now directly owns 124,522 shares of the company’s stock, valued at approximately $10,766,172.12. The sale was disclosed in a filing with the SEC, which is accessible through this link.
Eli Lilly and Company (NYSE LLY) traded up $0.04 during mid-day trading on Wednesday, reaching $86.71. The company had a trading volume of 4,252,500 shares, compared to its average volume of 3,674,671. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66. Eli Lilly and Company has a one year low of $67.54 and a one year high of $89.09. The company has a market cap of $96,780.00, a price-to-earnings ratio of 21.19, a PEG ratio of 1.90 and a beta of 0.35.
Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, beating the consensus estimate of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The business had revenue of $5.66 billion for the quarter, compared to the consensus estimate of $5.52 billion. During the same period last year, the business posted $0.88 EPS. The company’s revenue was up 9.0% compared to the same quarter last year. equities research analysts predict that Eli Lilly and Company will post 4.21 earnings per share for the current year.
LLY has been the subject of several research reports. Goldman Sachs Group reissued a “buy” rating and issued a $95.00 target price (up previously from $92.00) on shares of Eli Lilly and in a research report on Thursday, October 5th. Cowen reissued a “buy” rating and issued a $95.00 target price on shares of Eli Lilly and in a research report on Wednesday, October 4th. Jefferies Group reissued a “buy” rating and issued a $89.00 target price on shares of Eli Lilly and in a research report on Monday, September 11th. Piper Jaffray Companies reissued a “buy” rating and issued a $103.00 target price on shares of Eli Lilly and in a research report on Thursday, August 31st. Finally, Zacks Investment Research raised Eli Lilly and from a “hold” rating to a “buy” rating and set a $95.00 target price for the company in a research report on Thursday, October 26th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have given a buy rating to the stock. Eli Lilly and presently has an average rating of “Hold” and an average target price of $90.25.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. boosted its stake in Eli Lilly and by 2.3% during the 2nd quarter. Vanguard Group Inc. now owns 70,207,891 shares of the company’s stock valued at $5,778,109,000 after purchasing an additional 1,610,885 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Eli Lilly and by 2.1% in the 2nd quarter. BlackRock Inc. now owns 63,583,747 shares of the company’s stock worth $5,232,942,000 after buying an additional 1,323,259 shares during the last quarter. Janus Henderson Group PLC boosted its stake in shares of Eli Lilly and by 16.1% in the 3rd quarter. Janus Henderson Group PLC now owns 10,857,193 shares of the company’s stock worth $928,719,000 after buying an additional 1,503,918 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Eli Lilly and by 8.4% in the 1st quarter. Geode Capital Management LLC now owns 9,103,975 shares of the company’s stock worth $764,597,000 after buying an additional 708,597 shares during the last quarter. Finally, Janus Capital Management LLC boosted its stake in shares of Eli Lilly and by 2.8% in the 1st quarter. Janus Capital Management LLC now owns 8,723,692 shares of the company’s stock worth $733,731,000 after buying an additional 237,619 shares during the last quarter. Institutional investors and hedge funds own 76.42% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/13/jeffrey-n-simmons-sells-12500-shares-of-eli-lilly-and-company-lly-stock.html.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.